TAKE Solutions Past Earnings Performance
Past criteria checks 0/6
TAKE Solutions's earnings have been declining at an average annual rate of -9.7%, while the Healthcare Services industry saw earnings growing at 13% annually. Revenues have been declining at an average rate of 50.9% per year.
Key information
-9.7%
Earnings growth rate
-9.7%
EPS growth rate
| Healthcare Services Industry Growth | 16.1% |
| Revenue growth rate | -50.9% |
| Return on equity | n/a |
| Net Margin | -182.3% |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Recent updates
More Unpleasant Surprises Could Be In Store For TAKE Solutions Limited's (NSE:TAKE) Shares After Tumbling 26%
Mar 09
We Think TAKE Solutions (NSE:TAKE) Has A Fair Chunk Of Debt
Jul 15Is TAKE Solutions (NSE:TAKE) A Risky Investment?
Mar 21Does TAKE Solutions (NSE:TAKE) Have A Healthy Balance Sheet?
Jul 13Here's Why TAKE Solutions (NSE:TAKE) Can Manage Its Debt Responsibly
Dec 09TAKE Solutions (NSE:TAKE) Is Making Moderate Use Of Debt
Jul 02Here's Why TAKE Solutions (NSE:TAKE) Can Afford Some Debt
Mar 09Here's What TAKE Solutions Limited's (NSE:TAKE) Shareholder Ownership Structure Looks Like
Feb 02TAKE Solutions' (NSE:TAKE) Stock Price Has Reduced 69% In The Past Five Years
Dec 29We Think TAKE Solutions (NSE:TAKE) Has A Fair Chunk Of Debt
Nov 19Reflecting on TAKE Solutions' (NSE:TAKE) Share Price Returns Over The Last Five Years
Sep 28Here's Why TAKE Solutions (NSE:TAKE) Has A Meaningful Debt Burden
Aug 04Revenue & Expenses Breakdown
How TAKE Solutions makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 656 | -1,196 | 27 | 0 |
| 31 Dec 23 | 899 | -144 | 27 | 0 |
| 30 Sep 23 | 1,238 | -227 | 27 | 0 |
| 30 Jun 23 | 1,491 | -483 | 27 | 0 |
| 31 Mar 23 | 1,891 | -469 | 27 | 0 |
| 31 Dec 22 | 1,976 | -795 | 56 | 0 |
| 30 Sep 22 | 3,514 | -1,111 | 56 | 0 |
| 30 Jun 22 | 5,039 | -911 | 0 | 0 |
| 31 Mar 22 | 6,526 | -828 | 54 | 0 |
| 31 Dec 21 | 8,350 | -1,220 | 139 | 0 |
| 30 Sep 21 | 8,440 | -1,058 | 139 | 0 |
| 30 Jun 21 | 8,173 | -2,146 | 139 | 0 |
| 31 Mar 21 | 7,740 | -4,534 | 139 | 0 |
| 31 Dec 20 | 9,237 | -5,433 | 871 | 0 |
| 30 Sep 20 | 13,584 | -4,672 | 871 | 0 |
| 30 Jun 20 | 17,960 | -2,995 | 871 | 0 |
| 31 Mar 20 | 22,129 | -124 | 715 | 0 |
| 31 Dec 19 | 23,762 | 1,734 | 920 | 0 |
| 30 Sep 19 | 22,467 | 1,588 | 920 | 0 |
| 30 Jun 19 | 21,542 | 1,690 | 920 | 0 |
| 31 Mar 19 | 20,390 | 1,773 | 920 | 0 |
| 31 Dec 18 | 19,590 | 1,953 | 826 | 0 |
| 30 Sep 18 | 18,454 | 2,006 | 826 | 0 |
| 30 Jun 18 | 17,004 | 1,778 | 826 | 0 |
| 31 Mar 18 | 15,872 | 1,605 | 826 | 0 |
| 31 Dec 17 | 14,888 | 1,424 | 711 | 0 |
| 30 Sep 17 | 14,239 | 1,383 | 711 | 0 |
| 30 Jun 17 | 13,813 | 1,324 | 0 | 0 |
| 31 Mar 17 | 13,446 | 1,431 | 717 | 0 |
| 31 Dec 16 | 13,011 | 1,274 | 153 | 0 |
| 30 Sep 16 | 12,058 | 1,192 | 153 | 0 |
| 30 Jun 16 | 11,192 | 1,116 | 153 | 0 |
| 31 Mar 16 | 10,301 | 1,197 | 558 | 0 |
| 31 Dec 15 | 9,332 | 1,156 | 1,518 | 0 |
| 30 Sep 15 | 8,701 | 1,080 | 1,518 | 0 |
| 30 Jun 15 | 7,975 | 964 | 1,518 | 0 |
| 31 Mar 15 | 7,304 | 699 | 536 | 0 |
| 31 Dec 14 | 7,120 | 557 | 1,693 | 0 |
| 30 Sep 14 | 7,396 | 560 | 1,693 | 0 |
| 30 Jun 14 | 7,814 | 577 | 0 | 0 |
| 31 Mar 14 | 8,155 | 580 | 1,693 | 0 |
| 31 Dec 13 | 8,142 | 605 | 1,508 | 0 |
Quality Earnings: TAKE is currently unprofitable.
Growing Profit Margin: TAKE is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: TAKE is unprofitable, and losses have increased over the past 5 years at a rate of 9.7% per year.
Accelerating Growth: Unable to compare TAKE's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: TAKE is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare Services industry (11.9%).
Return on Equity
High ROE: TAKE's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.